argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 okt 2014 - 07:00
Statutaire naam
argenx SE
Titel
arGEN-X Completes Recruitment of First Cohort of 15 Patients with CD70-Positive Hematological Malignancies into its Phase 1b Expansion Trial with ARGX-110
Bericht
Based on evidence of activity, T-cell lymphomas selected as indication for initial efficacy studies
15 October 2014
Breda, the Netherlands / Ghent, Belgium - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, has completed enrolment of the first expansion cohort of 15 patients with CD70-positive hematological malignancies, part of an ongoing open-label Phase 1b trial with ARGX-110, a novel anti-CD70 therapeutic antibody.
Gerelateerde downloads
Datum laatste update: 19 december 2025